Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Longo

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Cancers|January 13, 2021
Molecular Heterogeneity of High Grade Colorectal AdenocarcinomaCristian Perna, Antonia Navarro, Ignacio Ruz-Caracuel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2022
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket studyFederico Longo-Muñoz, Daniel Castellano, Jerome Alexandre, et al.
Pharmacological Research|September 15, 2018
Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecanSara Salvador-Martín, Xandra García-González, María I García, et al.
Pharmacological Research|March 29, 2017
Identification of new SNPs associated with severe toxicity to capecitabineMarta Pellicer, Xandra García-González, María I García, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 8, 2022
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, et al.
Cancers|April 13, 2023
Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 InhibitorsCristina Saavedra, Alejandro Vallejo, Federico Longo, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysisSalvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Pharmacogenomics|July 27, 2017
Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicityMarta Pellicer, Xandra García-González, María I García, et al.
Cancer|July 20, 2024
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 StudyHyun Cheol Chung, Esma Saada-Bouzid, Federico Longo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancerEric Van Cutsem, Robert J Mayer, Stéphanie Laurent, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Cancers|January 13, 2021
Molecular Heterogeneity of High Grade Colorectal AdenocarcinomaCristian Perna, Antonia Navarro, Ignacio Ruz-Caracuel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2022
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket studyFederico Longo-Muñoz, Daniel Castellano, Jerome Alexandre, et al.
Pharmacological Research|September 15, 2018
Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecanSara Salvador-Martín, Xandra García-González, María I García, et al.
Pharmacological Research|March 29, 2017
Identification of new SNPs associated with severe toxicity to capecitabineMarta Pellicer, Xandra García-González, María I García, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 8, 2022
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, et al.
Cancers|April 13, 2023
Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 InhibitorsCristina Saavedra, Alejandro Vallejo, Federico Longo, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2020
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysisSalvador Fudio, Josep Tabernero, Vivek Subbiah, et al.
Pharmacogenomics|July 27, 2017
Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicityMarta Pellicer, Xandra García-González, María I García, et al.
Cancer|July 20, 2024
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 StudyHyun Cheol Chung, Esma Saada-Bouzid, Federico Longo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancerEric Van Cutsem, Robert J Mayer, Stéphanie Laurent, et al.
Pageof 7